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Genetic testing is becoming increasingly used to detect individuals who are 
predisposed to developing cancer. If genetic testing identifies a variant in an individual’s 
DNA, the testing laboratory uses available data to classify the variant as either disease-
causing or benign. When limited data is available regarding a variant’s pathogenicity and 
the risk of cancer for an individual is not clear, the variant is classified as a “variant of 
uncertain significance” (VUS). If new data is discovered, the VUS may be reclassified. 
There is a gap in current literature regarding desired communication for a reclassified 
genetic test result. There are no standard guidelines for healthcare providers regarding 
communication of a reclassified VUS result. This study aimed to explore communication 
preferences of past Prisma Health patients with a VUS result on cancer genetic testing. A 
total of 34 participants responded to the anonymous online questionnaire. Participants 
reported telephone call by a genetic counselor as the most preferred communication for 
an upgraded VUS result and a letter in the mail as the most preferred communication for 
a downgraded VUS result. There was no significant difference in communication 
preferences for upgraded versus downgraded VUS results. A majority of participants 
reported mild concern regarding their VUS result. Overall, this study determined that 
patients want to be contacted regarding a reclassified VUS result, but there is no clear 
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CHAPTER 1  
BACKGROUND 
The molecular basis of cancer is fundamentally ‘genetic’ at the cellular level- all 
tumors are caused by mutations in either proto-oncogenes or tumor suppressor genes 
(Evans & Woodward, 2020). Most of these mutations are acquired throughout one’s 
lifetime and cannot be passed on to future generations. However, mutations in a proto-
oncogene or tumor suppressor gene can sometimes be inherited. Of all cancer diagnoses, 
about 5-10% have a genetic predisposition. Having mutations present in certain genes 
increases one’s risk of developing certain types of cancer (Domchek et al., 2013). 
Identifying patients with genetic predispositions to cancer is clinically important to help 
guide treatment, make surgical decisions, and test at-risk family members (Evans & 
Woodward, 2020). Cancer research continues to identify more genes that are associated 
with an increased risk for developing cancer in the presence of a mutation. 
Germline genetic testing is used in the oncology setting to help identify 
individuals who are predisposed to developing cancer. Germline genetic testing requires 
DNA samples that can typically be obtained from blood, saliva, or fibroblasts. A genetic 
test can be ordered to analyze one specific gene mutation through single site testing, or it 
can be ordered as a multi-gene panel to analyze many genes at one time. Different 
laboratories have different genes on their panels and each gene is associated with a 
specific cancer risk profile (Hiraki et al., 2014). The genetic test is typically done by next 
generation sequencing (NGS), which identifies specific inherited variants in a person’s 
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genes. NGS is a massive parallel sequencing technology that allows large amounts of 
genetic information fragments (DNA and RNA) to be sequenced simultaneously 
(Shendure & Ji, 2008). The field of medical genetics continues to evolve and advance, 
which allows for lower costs of genetic testing and more rapid results from NGS (Rehm 
et al., 2013). These factors are thus leading to more individuals choosing to undergo 
genetic testing in many specialties, including cancer. The use of genetic testing in 
medicine is beneficial to a patient because it can help inform healthcare management 
(Esterling et al., 2020).  
1.1 Variant Interpretation 
When genetic testing is completed, the final report describes the interpretation of 
variants detected. Variant interpretation is used to classify a variant based on where it 
falls on a scale from disease-causing to benign. The classification of a variant is based on 
different criteria. Some factors that are assessed include population data, computational 
data, functional data, and segregation data. There are many classification systems offered 
for annotating genetic variants (Halverson, 2019; Shoenbill et al., 2014). A five-tier 
terminology system is strongly recommended by the American College of Medical 
Genetics and Genomics (ACMG) (Richards et al., 2015). The five-tier classification 
system gives a variant one of five modifiers: pathogenic, likely pathogenic, uncertain 
significance, likely benign, or benign. ACMG recommends using the word “likely” as a 
variant’s modifier only when the interpretation is at least 90% certain that the variant is 
disease-causing or harmless (Richards et al., 2015). The five-tier classification system is 
used to assist healthcare providers in understanding pathogenicity of a variant and to 
make management recommendations based on the findings. 
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When a variant is “pathogenic” or “likely pathogenic,” there is sufficient evidence 
to assume a clinical effect from the variant. For genes that regulate cell growth, a 
pathogenic variant puts an individual at a higher risk of developing cancer. The 
healthcare team may use a “pathogenic” or “likely pathogenic” variant to make surgical 
decisions, implement risk-reducing strategies, and increase screenings. When a 
“pathogenic” or “likely pathogenic” variant is identified, testing should be offered to 
family members who may also be at increased risk (Chang et al., 2019). A pathogenic 
variant is reported to represent less than 20% of variants in high-risk cancer genes 
(Moghadasi et al., 2016). 
Two other possible variant classifications include “likely benign” and “benign.” 
These variants are often not reported to patients and their genetic test result is described 
to be negative, with no variants identified that would indicate the patient has a higher risk 
to develop cancer (Susswein et al., 2016). The healthcare team usually recommends 
against making surgical decisions based solely on a negative genetic test report. A 
patient’s personal and family history is typically utilized to guide their management. 
1.2 Variant of Uncertain Significance (VUS) 
The fifth classification on the five-tier system is a variant of “uncertain 
significance” (VUS). This classification is used when there is limited data available on 
the pathogenicity of the variant and the impact on the individual’s cancer risk is unknown 
(Lazaridis et al., 2016; Richards et al., 2015). Often, uncertain variants are lacking data 
on the impact the variant has on the resulting protein and/or its function, and therefore the 
clinical effect is unable to be determined. VUS results consist mainly of missense 
mutations, meaning a single nucleotide is different from the reference sequence, which 
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may lead to an incorrect amino acid. Occasionally, variants can be found to disrupt RNA 
splicing, but the end effect is unknown (Eggington et al., 2013). It is not recommended 
that medical management recommendations for patients be made based on a VUS result 
alone since there is a lack of information surrounding the variant (Makhnoon et al., 
2019). Similar to a negative result, the person should be managed based on their personal 
and family history. When a person is found to have a variant that is classified as a VUS, it 
is not typically recommended that other family members undergo genetic testing for the 
specific variant (Gradishar et al., 2020). Patients who have a VUS result have reported 
feeling distrust towards healthcare providers, uncertainty surrounding the results and the 
impact on their clinical management, and concern for their family’s risk (Makhnoon et 
al., 2019). VUS results are monitored by the testing laboratory and will be reclassified if 
new data is introduced that allows the uncertain result to become a definitive answer. 
Family studies or other research options may be available to some patients who have a 
VUS result to aid variant reclassification efforts (Garrett et al., 2016). 
1.3 VUS Rates 
With the increasing rate of referrals to genetics and better access to genetic 
counseling services, more people are able to pursue genetic testing. This increase leads to 
a higher diagnostic yield, along with an increase in discovery of new unclassified genetic 
variants, which are often labeled as variant(s) of uncertain significance (VUS). 
Additionally, with the integration of multi-gene panel testing, there have been more VUS 
reports because of an increase in unique variants being discovered (Medendorp et al., 
2018). One study by Federici and Soddu (2020) analyzed panel testing results for 
hereditary breast and ovarian cancers and concluded that NGS is able to find many 
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variants, but 40% of those are classified as variants of uncertain significance. However, 
as more data is gathered for different genes and technology improves, the chance of 
identifying a VUS decreases because the interpretation of variants improves (Karam et 
al., 2019; Mauer et al., 2013). Myriad Genetics reports lower VUS results for the BRCA1 
and BRCA2 genes because of decades of genetic testing they have done, allowing for 
more research and data of the two genes (Cheon et al., 2014). Eggington et al. (2013) 
reported that Myriad Genetics’ VUS rates went from 12.8% to 2.1% for BRCA1 and 
BRCA2 from 2002 to 2013. Although there are guidelines for variant classification, 
clinical molecular genetic laboratories can classify variants differently depending on their 
internal data (Hoskinson et al., 2018). 
With advancement of RNA genetic testing, Ambry Genetics has begun to use 
DNA and RNA analysis to improve diagnostic outcome of DNA genetic testing (Karam 
et al., 2019). RNA analysis can provide information about the functional status of a DNA 
variation. It has been estimated that 15% to 25% of DNA variants found in hereditary 
cancer genes are known to interrupt RNA splicing, but the alterations were classified as a 
VUS because of missing functional status of RNA (Karam et al., 2019). RNA genetic 
testing was able to clarify 88% of inconclusive genetic testing results found from DNA in 
a small sample (Karam et al., 2019). As new information becomes available, a VUS may 
be reclassified to any one of the other classifications. Reclassification of a VUS result 
could have implications for a patient and other family members (Murray et al., 2011). 
1.4 Variant Reclassification 
Variant reclassification does not frequently occur; however, clinical management 
recommendations for patients and relatives may change if a variant’s classification is 
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reclassified (Mersch et al., 2018; Slavin et al., 2019). A reclassification of a VUS may 
occur, although for more rare variants, reclassification may never happen (Lindor et al., 
2013). In 2018, a retrospective analysis was done to determine the prevalence of variant 
reclassifications following cancer genetic testing. Of the 1.67 million tests analyzed, only 
24.9% of results were reclassified (Mersch et al., 2018). A majority of variants of 
uncertain significance were downgraded to “likely benign” or “benign”. A variant is 
downgraded when sufficient data is available to support decreasing the level of 
pathogenicity originally assigned. A variant can be upgraded, but studies indicate this 
happens less often (Mersch et al., 2018). A VUS can be upgraded when enough data 
becomes available to support that a variant is deleterious, an alteration that increases 
one’s susceptibility to developing cancer. A VUS that becomes likely pathogenic or 
pathogenic may have clinical management recommendations not previously indicated for 
the patient. The patient may be eligible for additional interventions to lower their risk of 
developing cancer, preventing it from occurring, or detecting it at an earlier stage. 
Additionally, family cascade testing can be considered (Halverson, 2019; Halverson et 
al., 2020). For a reclassified genetic test result, ACMG released a statement declaring 
clinical laboratories have a responsibility to issue formal variant results (including 
reclassified and updated variant interpretations) to clinicians. ACMG also suggested that 
laboratories update the information on public databases with a summary of the evidence 
that led to the classification or reclassification (Deignan et al., 2019). 
1.5 Genetic Testing Pretest and Posttest Counseling  
Clinically, there are complexities and limitations surrounding genetic testing for 
cancer predispositions, so it is important to have clear pretest and posttest counseling. 
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The standard of care in clinical practice is that a certified genetic counselor or other 
clinical genetics specialist should disclose genetic test results (Roberts et al., 2010). 
During pretest counseling, it is crucial to inform the patient of possible results, including 
a VUS result. Additionally, posttest counseling is important to educate patients about 
their result, including implications and limitations of the test. For posttest counseling, it is 
the healthcare provider’s responsibility to attempt to contact the patient to inform them of 
their genetic testing results (Patrick-Miller et al., 2014). In the case of a reclassification, 
the healthcare provider has an ethical obligation, based on the principle of beneficence, to 
at least try to re-contact a patient in situations that may alter medical care (David et al., 
2018). 
1.6 Patient Communication 
Delivery of healthcare information is important to establish patient-provider 
confidence. To have an effective healthcare appointment, there needs to be positive 
patient-physician interaction that is built on trust, communication, and fair intervention 
(LaRocque et al., 2015). It is critical that providers share results of a test in the most 
confidential and patient-oriented method (Boohaker et al., 1996). Liederman and 
Morefield (2003) investigated the preferred communication method of patients who 
visited their primary care physician’s office. This revealed that patients are comfortable 
getting results through password-protected patient portals, which is sometimes preferred 
over a phone call (Liederman & Morefield, 2003). Alternatively, studies have compared 
delivering information over the phone versus in person, which determined that sharing 
results from a cancer susceptibility genetic test has the same impact when delivered in 
person or over the phone (Jenkins et al., 2007; Platten et al., 2012). Another study was 
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done to investigate patient satisfaction with in-person versus telephone delivery of 
results. The survey was mailed to 379 patients, some of whom had in person result 
disclosure while others had telephone result disclosure. All patients had BRCA1 and 
BRCA2 genetic testing done at a cancer clinic. In general, they concluded that patients 
reported being satisfied with their result disclosure and there was no significant 
difference in satisfaction between patients who received the result in person compared to 
over the telephone (Baumanis et al., 2009). Additionally, LaRocque et al. (2015) 
researched patient’s preferences for receiving reports of test results. This was done by 
surveying 409 participants who reported their comfort level of many communication 
preferences for a variety of test results including blood cholesterol, colonoscopy, sexually 
transmitted infections, and genetic test results. This study suggested the comfort level of 
method of communication was affected by the type of test result being disclosed. It was 
found that 32.6% of patients surveyed were comfortable with a voicemail for common 
test results, but only 18.1% were comfortable with a voicemail for genetic test results. 
Higher levels of comfort were noted for the use of password protected portals- 58.8% of 
patients surveyed were comfortable with portals for common test results and 46.3% were 
comfortable for genetic test results. The study also found that as a patient’s age increases, 
the comfort level with receiving a letter increases (LaRocque et al., 2015).  
In 2019, a study was conducted to see how different communication techniques of 
cancer screening results affected patient’s anxiety, understanding, and preferences. This 
showed that communication through direct methods (i.e., telephone or in person) were 
preferred and led to better understanding of the results compared to the less direct 
methods of communication (i.e., letter in the mail). The study could not make a clear 
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conclusion of which communication technique would result in less anxiety (Williamson 
et al., 2019). When returning test results, they need to be communicated clearly and 
accurately to help reduce a patient’s anxiety while also increasing their understanding of 
the result (Litchfield et al., 2014). Marcus et al. (2012) performed a study to determine 
women’s preferences of learning their mammogram results. This study found that direct 
verbal communication of results with printed supporting material was preferred because 
of the complexities that were discussed. The study found that there was a 
misunderstanding of only a result letter due to patient misinterpretation of the language 
utilized by the healthcare provider (Marcus et al., 2012). Studies have shown that 
misinterpretation of patient letters can be caused by the content included and language 
used; researchers concluded that this is due to the education level of the patient (Marcus 
et al., 2012; McCaffery & Irwing, 2005). The misinterpretation of letters was seen less 
frequently when a patient received a call first followed by a letter (Williamson et al., 
2019).  
 Though there is some research regarding a patient’s preference for receiving test 
results, there is a gap in the literature regarding desired communication for a reclassified 
genetic test result. There is no research, to our knowledge, that has been conducted to 
assess patient communication preferences for a reclassified VUS genetic test result. There 
are currently no standard guidelines for healthcare providers regarding method of 
delivery of reclassified results (Halverson et al., 2019). VUS results are reclassified more 
frequently because of the increased information being learned and advances in 
technology (Karam et al., 2019). Although there are more VUS results being reclassified, 
there is no standard method for communication of this updated information to patients. 
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When trying to establish a communication method for patients, it is important to consider 
how a patient prefers to be told of their reclassified result. Overall, it would benefit 
patients for cancer genetic counselors to have a standardized method of disclosing 
reclassified VUS test results to ensure consistent and effective communication for all 
patients.   
1.8 Aim of Study 
This study utilized an original questionnaire with questions designed to assess 
primarily quantitative data. The goal of the questionnaire was to ask Prisma Health 
Genetic Counseling patients with a VUS result on cancer genetic testing to reflect upon 
preferred communication strategies if their results were to be reclassified. Patients may 
ultimately benefit by their communication preferences being taken into consideration in 
clinical practice. Additionally, cancer genetic counselors may benefit from this study as 
the findings are expected to directly impact their clinical practice. 
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CHAPTER 2  
EXPLORATION OF PATIENT COMMUNICATION PREFERENCE REGARDING 






















Genetic testing is increasingly used to detect individuals who are predisposed to 
developing cancer. If genetic testing identifies a variant in an individual’s DNA, the 
testing laboratory uses available data to classify the variant as either disease-causing or 
benign. When limited data is available regarding a variant’s pathogenicity and the risk of 
cancer for an individual is not clear, the variant is classified as a “variant of uncertain 
significance” (VUS). If new data is discovered, the VUS may be reclassified. There is a 
gap in current literature regarding desired communication for a reclassified genetic test 
result. There are no standard guidelines for healthcare providers regarding 
communication of a reclassified VUS results. This study aimed to explore 
communication preferences of past Prisma Health patients with a VUS result on cancer 
genetic testing. A total of 34 participants responded to an anonymous online 
questionnaire. Participants reported telephone call by a genetic counselor as the most 
preferred communication for an upgraded VUS result and a letter in the mail as the most 
preferred communication for a downgraded VUS result. There was no significant 
difference in communication preferences for upgraded versus downgraded VUS results. 
A majority of participants reported mild concern regarding their VUS result. Overall, this 
study determined that patients want to be contacted regarding a reclassified VUS result, 
but there was no clear consensus on the most preferred method.  
2.2 Introduction 
Having a mutation or a harmful variant present in certain genes is known to 
increase one’s likelihood of developing certain types of cancer (Domchek et al., 2013). 
Of all cancer diagnoses, about 5-10% are found to have a genetic predisposition. 
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Germline genetic testing is offered to people with specific personal or family histories of 
cancer. The testing is typically done by Next Generation Sequencing (NGS) and is used 
to assess for inherited pathogenic variants to help identify individuals who are 
predisposed to developing cancer. This information can be helpful for patient’s medical 
management and for informing family members who may also have a genetic 
predisposition. After genetic testing is completed, the final report includes a detailed 
interpretation of detected variants.  
Variant classification is based on criteria that determines where the variant falls 
on a scale from deleterious to benign. The American College of Medical Genetics and 
Genomics (ACMG) recommends laboratories use the five-tier terminology system for 
classifying variants (Richards et al., 2015). Through the use of the five-tier classification 
system, a variant is labeled with one of five modifiers: pathogenic, likely pathogenic, 
uncertain significance, likely benign, or benign. A variant that has been classified as 
“pathogenic” or “likely pathogenic” had sufficient evidence known to the laboratory 
allowing for it to be designated as clinically significant. Variants that are categorized as 
“likely benign” and “benign” are often reported to patients as a negative test result. This 
means that no variant was identified to indicate the patient had a higher   risk of 
developing cancer (Susswein et al., 2016). For patients with a variant that was found to 
be “likely benign” or “benign”, it is typically recommended they base their medical 
management on the patient’s personal and family history. The fifth category on the five-
tier system is “uncertain significance” (VUS). When a laboratory has limited data 
available for the variant’s pathogenicity and the impact towards the individual’s risk for 
cancer is unknown, then the variant is classified as a VUS (Lazaridis et al., 2016; 
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Richards et al., 2015). Currently, it is not recommended that a patient’s medical 
management be changed and/or made based on a VUS result alone (Makhnoon et al., 
2019).    
More people have the opportunity to pursue genetic counseling due to increased 
rate of referrals and more ways to access this service. This leads to more people 
undergoing genetic testing, which results in increased diagnostic yield. Additionally, 
there is an increase in the detection of novel unclassified genetic variants, which often 
have limited functional information, resulting in a VUS classification. VUS results are 
continuously monitored by the testing laboratory. If new data is discovered that allows 
the uncertain result to become more definitive, then the VUS will be reclassified to one of 
the other classifications (Garrett et al., 2016). VUS reclassification may impact medical 
management for the patient and other family members (Murray et al., 2011). A majority 
of VUS results that are reclassified become downgraded to “likely benign” or “benign”, 
which means sufficient data became available to suggest little or no clinical effect from 
the variant. Other VUS results may be upgraded, but studies indicate this happens less 
often (Mersch et al., 2018). A VUS is upgraded when data proves that the variant is 
harmful. When a VUS is upgraded, there may be changes made to their medical 
management and appropriate family testing may be considered (Halverson, 2019; 
Halverson et al., 2020).   
When giving healthcare information to patients, it is imperative to have 
established patient-provider confidence. This means that the healthcare provider was able 
to build trust with the patient, have clear communication, and fair intervention (LaRocque 
et al., 2015). When sharing test results, it is important that providers share the results 
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confidentially and in a patient-oriented manner (Boohaker et al., 1996). One way to 
ensure that healthcare providers share test results with a patient-oriented method is by 
considering preferred communication techniques. Studies have compared patient 
preference for receiving information over the phone versus in person. These studies 
revealed that disclosing cancer susceptibility genetic test results in person or over the 
phone had the same impact on patients (Jenkins et al., 2007; Platten et al., 2012). Another 
study investigated the preferred communication method of patients in a primary care 
setting. The study concluded that many patients are content with getting results through 
password-protected portals, which can be preferred over a phone call (Liederman & 
Morefield, 2003).  
Different types of communication have been shown to impact patient’s anxiety 
and understanding of information. To reduce patient’s anxiety about test results, they 
need to be communicated clearly and accurately (Litchfield et al., 2014). A study was 
conducted in 2019 to understand how altered methods of communication affected 
patient’s anxiety, understanding, and preferences when receiving cancer screening 
results. This study concluded that contact through direct communication methods were 
preferred by patients and ultimately resulted in better comprehension of the results. 
However, the study could not determine which communication technique resulted in less 
anxiety (Williamson et al., 2019).  
Currently, cancer genetic counseling literature emphasizes rising rates of VUS 
reclassification results and briefly explores patient perspectives when there is a 
reclassification of their VUS. With improved technology and an increase in referrals for 
cancer genetic testing, more people are pursuing multi-gene panel tests and thus 
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increasing the amount of available genetic data. It is relatively common for a panel test to 
result in a variant of uncertain significance. As more is understood about cancer 
susceptibility genes, laboratories are able to reclassify previously identified variants to 
either benign or pathogenic. With every step forward, there remains the question of how 
best to disclose a reclassified result to a patient. The key element of patient preference for 
being informed of a change in their test result remains unexamined, resulting in a lack of 
a standardized method to deliver reclassified VUS results.  
There are a number of ways that a patient could be notified of a reclassified VUS 
result, including a telephone call, an in-person appointment, a secure message on a portal, 
or a letter by U.S. mail. With many different options to inform patients, there is no 
standardized communication mode being utilized in the field of genetic counseling. 
Effective interaction between healthcare providers and patients is primarily dependent 
upon communication. In order to have successful communication, it is important for 
healthcare providers to incorporate patient preferences when deciding upon a 
communication method. 
This study was conducted to determine the paramount way for genetic counselors 
to communicate reclassified test results with patients. This study considered how the 
mode of communication might change if the VUS was upgraded, if the VUS was 
downgraded, or if multiple VUS results were identified. This study also investigated 
patient communication with relatives regarding a VUS result and if the level of concern a 
patient expresses about their VUS result correlates to a desire for a specific method of 
communication. The ultimate goal of this study was to make recommendations to cancer 
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genetic counselors about patients’ preferred method for disclosing reclassified VUS 
results. 
We hypothesized that patients' desired form of communication would differ 
depending on the reclassified result received. We expected patients who have a VUS 
downgraded would be more comfortable with a less personalized communication 
method, while a patient with a VUS that is upgraded would prefer a more direct 
communication method. Lastly, it was predicted that patients with more than one VUS 
identified may only want to be contacted if one of the results was upgraded to likely 
pathogenic. 
2.3 Methods 
2.3.1 Participants and Recruitment 
This study was approved by the institutional review board at the University of 
South Carolina in June of 2020. The primary aim of this research was to assess how 
patients desired to receive reclassified VUS results from cancer genetic testing. 
Therefore, participation was limited to Prisma Health Genetic Counseling patients who 
had a VUS result on a cancer genetic test within the last two years. Individuals were 
excluded if they already had their VUS result reclassified, had a pathogenic result in 
addition to the VUS result, are non-English speaking, or are under age 18.  
Recruitment for this study was done with the aid of Prisma Health cancer genetic 
counselors who had records of past patients with a VUS result. An invitation letter was 
mailed to eligible patients from their genetic counselor (Appendix A). The letter was 
included in current VUS results sent to patients by the cancer genetic counselors during 
the data collection period while also being mailed to patients who had cancer genetic 
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testing with at least one VUS result over the past 2 years. Due to low questionnaire 
response rates, a second invitation letter was mailed to a subset of the original eligible 
patients from their genetic counselor (Appendix B). 
An anonymous online questionnaire was used in this study. Participation in the 
questionnaire was voluntary. Participants were informed that they could withdraw from 
the questionnaire at any time by not completing the questionnaire. Once the participant 
entered the anonymous link or utilized the QR code in the invitation letter, the 
questionnaire welcome page detailed the background and purpose of the study, expected 
duration, eligibility requirements, and information regarding consent (Appendix C). 
There were multiple screening questions in the questionnaire, and any participant who 
was not eligible had their data deleted from analysis. A total of 273 individuals were 
originally contacted to invite them to participate in the online survey. Of the original 273, 
100 people were randomly selected using a random number generator to be recontacted 
to participate in the online survey. A total of 34 participants completed the online 
questionnaire, and the demographic information can be seen in Table 2.1. Questionnaire 
responses were recorded from June 25th, 2020 to December 15th, 2020.  
Following completion of the questionnaire, participants were shown the closing 
screen of the questionnaire which included a thank you for their participation and a link 
to enter a raffle (Appendix E). To incentivize participation, questionnaire participants 
could enter a raffle to win one of five $20.00 Amazon gift cards. Participants were 
consented again before entering the raffle (Appendix F). To enter the raffle, participants 
provided their name and preferred email (Appendix G). Entering in the raffle was 
optional and the email addresses were not linked to the questionnaire responses. At the 
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end of the questionnaire response period, five participants were randomly selected using 
online software.  
2.3.2 Instrumentation  
The online questionnaire was developed through Qualtrics.com (Appendix D). 
The questionnaire included items about the patient’s VUS result as well as the preferred 
method of notification if the VUS result was reclassified. The questionnaire had 22 items. 
There were two questions for participants to rank their preferences regarding 
communication methods, two free-response question, and 18 multiple choice questions. 
Skip logic was utilized for participants who answered that they had a single VUS result, 
so they would not answer questions regarding multiple VUS results. Demographic 
information questions were placed at the end of the questionnaire to learn participant’s 
age, sex, race, and level of education. 
2.3.3 Data Analysis 
Qualtrics.com software was utilized to collect participant response from June 25th, 
2020 to December 15th, 2020, then participant responses were downloaded for analysis. 
For quantitative analysis, the data was transferred from Microsoft Excel spreadsheets to 
Statistical Package for Social Sciences (SPSS). To address the research goal, descriptive 
statistics, including frequencies and percentages, were calculated. Independent T-Tests 
were utilized to analyze rank order questions to identify significant differences between 
patient’s communication preference for an upgraded VUS and a downgraded VUS result. 
Chi-squared Tests for Independence were used to analyze associations between various 
categorical variables. The qualitative responses produced from free response questions 
were utilized to enhance data from the quantitative analysis.  
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2.4 Results 
2.4.1 Communication Method Preferences for Upgraded Versus Downgraded 
Of the 34 participants, 47.06% ranked telephone call by a genetic counselor as 
their most preferred communication method for an upgraded VUS result. Alternatively, 
50.00% (n = 34) of participants ranked letter in mail as their most preferred 
communication preference for a downgraded VUS results (Figure 2.1).  
The majority of participants ranked telephone call by a genetic counselor 
(47.06%) as the most preferred method of communication for an upgraded VUS result. 
The ranking system went to six, but if a participant left it blank then that was 
automatically the sixth choice (least preferred). The majority of participants (79.41%) left 
the sixth choice blank. The least preferred communication method that was selected for 
an upgraded VUS result was secure web-portal (35.29%) (Table 2.2). 
Half of participants ranked letter in the mail (50.00%) as their most preferred 
method of communication for a downgraded VUS result. Again, the majority of 
participants (79.41%) left the sixth choice blank. The least preferred communication 
method that was selected for a downgraded VUS result was an in-person appointment 
with a genetic counselor (38.24%) (Table 2.3). 
Participants were assessed on which communication method they would not want 
utilized for notification of an upgraded VUS. In total, 47.06% of participants did not 
specify a communication method for this item. Of the participants who expressed a 
preference, the most selected answer (20.59%) was a secure web-portal notification 
(Figure 2.2). Additionally, participants were assessed on which communication method 
they would not want utilized for notification of a downgraded VUS result. In total, a 
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majority of participants (58.82%) did not specify a communication method for this item. 
Of the participants who expressed a preference, the most selected answers were an in-
person appointment with a genetic counselor (17.65%) and a secure web-portal 
notification (17.65%) (Figure 2.3). 
2.4.2 Communication Method Preferences for Multiple VUS Results 
Of the 34 participants who completed the survey, 19 (55.88%) reported having 
two or more VUS results. Of the 19 participants with multiple VUS results, 17 (89.47%) 
reported wanting to be contacted each time a VUS is changed, and 2 (10.53%) reported 
wanting to be notified only when all VUS results were changed (Figure 2.4). 
The 19 participants with multiple VUS results were asked about their most and 
least preferred communication method for being told of a single downgraded VUS result. 
One participant did not make a selection for this item. Of the 18 who responded to this 
item, half (50.00%) marked telephone call by a genetic counselor as their most preferred 
communication method. All 19 participants selected their least preferred communication 
method which was most often an in-person appointment with a genetic counselor 
(36.84%) (Figure 2.5).  
The 19 participants with multiple VUS results were questioned regarding their 
most and least preferred communication method for being told that all of their VUS 
results were reclassified. Of these participants, 18 selected their most preferred 
communication method. The majority of participants (61.11%) selected a telephone call 
by a genetic counselor as their most preferred communication method for all VUS results 
being reclassified. All 19 participants selected their least preferred communication 
method which was most often a letter in the mail (36.84%) (Figure 2.6). 
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When comparing the most preferred and least preferred method of 
communication, there was no statistical difference in mean between most and least 
preferred method of communication for only one VUS result being reclassified (M= -
0.63, SD=2.01, t(18)=1.37, p=0.19). Additionally, there was no statistical difference in 
mean between most and least preferred method of communication for all VUS results 
being reclassified (M= -0.63, SD=1.98, t(18)=1.39, p=0.18).  
2.4.3 Level of Concern Regarding VUS Result 
 Of the 34 participants who took the survey, 64.71% reported having a personal 
history of cancer. A majority of participants (59.09%) reported a personal history of 
breast and/or ovarian cancer (Figure 2.7). Of all participants, 91.18% reported having a 
family history of cancer. The majority of participants (61.29%) with a family history of 
cancer reported having multiple types of cancer in the family (Figure 2.8).  
The participants were queried on their level of concern about the VUS finding, 
and all 34 participants reported their level of concern. A majority of participants 
(55.88%) reported being “mildly concerned” (Table 2.4). Regarding how often 
participants think of their VUS result, 44.12% reported they rarely think about their VUS 
result (Figure 2.9). Concerned participants noted that they were “concerned because it’s a 
mutation but not enough is known”, that “the unknown is troubling”, and there is “… the 
possibility of [their] children inheriting the VUS”. A moderately concerned participant 
shared that to them, “no news is good news…”. Participants who reported being mildly 
concerned testified that they “rarely think about it”, are “mildly concerned when 
reminded of the variant”, and they “…would only think about it and be concerned if it 
[was] upgraded”. Participants who noted that they were not concerned made statements 
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including “I [was] the first family member to complete genetic testing, [and] doubt others 
will” and that “it's hard to understand what exactly all of it means, so to me, my Dr will 
advise me if I should worry”.  
2.4.4 Patient Communication of VUS Result 
Of the 34 participants, 33 participants disclosed if they discussed their VUS result 
with their family members. A majority of the participants (72.73%) reported sharing their 
VUS result with their family. All 33 respondents reported that they would tell their 
family if their VUS result was upgraded and 84.85% reported that they would tell their 
family if their VUS result was downgraded. Of the 34 participants, 33 reported on the 
amount of information they received at the time of receiving their VUS result. A majority 
of participants (84.85%) reported that they received the right amount of information 
when receiving their VUS result, while 15.15% reported wanting more information when 
receiving their VUS result.  
2.5 Discussion 
2.5.1 Communication Method Preferences for Upgraded Versus Downgraded 
While there is previous literature that investigated patient’s desired 
communication method when receiving initial test results, there is no apparent literature 
published that explores patient communication preferences for a reclassified VUS result. 
Since this has never been investigated, there are currently no standard guidelines for the 
healthcare field regarding the delivery of reclassified VUS results to patients (Halverson 
et al., 2019). To attempt to address this, rank order items were utilized for communication 
method rating because it highlights which communication methods are regarded as more 
or less favorable. Results of this study identified that the most preferred communication 
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method for an upgraded result differed from the most preferred communication method 
for a downgraded result.  
For an upgraded VUS result, participants desired a more direct communication 
method through a telephone call by a genetic counselor. Alternatively, participants 
desired a less direct communication method through a letter in the mail for a downgraded 
VUS result. An upgraded VUS result may have clinical management recommendations 
for a patient and family cascade testing that could require a more in-depth explanation for 
a patient, which could be conveyed better through a phone call (Halverson, 2019; 
Halverson et al., 2020). Interestingly, participants consistently ranked secure web-portal 
and in-person appointment with a genetic counselor as their two least preferred methods 
of communication for both upgraded and downgraded results. This suggests that in either 
situation, those would not be a desired communication method for being informed of a 
VUS reclassification. This finding differs from past research, including Liederman and 
Morefield (2003), who determined that patients were comfortable receiving results 
through patient portals, and sometimes patient portals were preferred over a phone call. 
However, secure web-portals limit a patient’s ability to ask questions pertaining to a 
reclassification, which could be a reason that participants did not prefer a secure web-
portal. Studies previously showed that sharing results from a cancer susceptibility genetic 
test had the same impact when delivered in person or over the phone (Jenkins et al., 2007; 
Platten et al., 2012). Participants preferred communication through a phone call 
compared to in-person, which could be due to convenience of a phone call that still offers 
direct communication, no wait or travel time for an appointment, and gives patients the 
ability to have questions answered immediately regarding results. While participants did 
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rank a top choice for an upgraded result and a downgraded result, there was no well-
defined order of preferred communication methods for this small sample size. This could 
be due to participants having no strong preference of communication. 
Most participants did not specify a communication method they would not want 
utilized for either an upgraded VUS or a downgraded VUS, which suggests that patients 
are open to a variety of communication methods. However, when participants did express 
a communication method that they would not want utilized, it was primarily secure web-
portal and in-person appointment with a genetic counselor. Again, this could be because a 
secure web-portal does not give patients the ability to ask questions directly to a 
healthcare provider and can be a barrier for people who do not have access to a computer 
or internet. Participants could perceive several disadvantages regarding an in-person 
appointment, such as the travel time and inconvenience of a genetic counseling 
appointment. This may include travel expenses, taking time off work, and the price of the 
appointment. Participants ranked speaking with a genetic counselor via telephone as a top 
choice for both upgraded and downgraded VUS results, so the selection of an in-person 
appointment with a genetic counselor is likely not due to the actual communication with a 
genetic counselor. Platten, et al. (2012) identified high satisfaction rates regarding cancer 
counseling conducted by telephone and in-person, and they suggested that the telephone 
model could be an equal or better alternative to in-person counseling, which is reflected 
from the participants’ rank order preferences in this study. This is also supportive of 
cancer genetics clinics being able to establish a standard protocol that works best for 
them, as some of these methods require greater time and effort from the clinic. 
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2.5.2 Communication Method Preferences for Multiple VUS Results 
 More than half of the initial participants who completed the questionnaire had 
multiple VUS results. We explored timing of when participants desired to be notified 
regarding a VUS reclassification and found that a majority of participants wanted to be 
contacted each time a VUS was changed, even if it would not result in altered 
management or have family testing implications. This could be because learning about 
one reclassification reduces the amount of uncertainty participants with multiple VUS 
results are experiencing. Additionally, we investigated how multiple VUS results would 
affect a participant’s preferred communication method regarding a single downgraded 
VUS result. Ultimately, participants claimed to want a telephone call by a genetic 
counselor for only one downgraded VUS result. This result was discordant with the initial 
information gathered when looking at everyone who participated. When asking about 
preferences, in general, participants selected letter in the mail as the most preferred 
method of communication for a downgraded result. However, when focusing on their 
specific finding of multiple VUS results, participants with multiple VUS results desired a 
telephone call by a genetic counselor. This result highlighted an inconsistency between 
patient preference of our entire cohort compared to those that received a result with 
multiple VUS. This is likely due to the fact that they may have more questions regarding 
their other remaining VUS results that may not be answered in a letter. Alternatively, 
participants with multiple VUS results least preferred method of communication for only 
one VUS result being downgraded was an in-person appointment with a genetic 
counselor, which was consistent with the initial information gathered. We believe that 
patients may consider the ability to ask questions and amount of information that they 
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receive over the phone as the same as going to an in-person appointment without the 
additional inconvenience of an in-person appointment. 
 Similarly, participants selected a telephone call by a genetic counselor as their top 
communication method preference for all VUS results being reclassified. This is a more 
complex result, which may lead to additional questions, leading patients to prefer a more 
direct communication method to learn of all their VUS results being reclassified. Having 
a telephone call by a genetic counselor selected as the top preference many times shows 
the importance of direct communication with a genetic counselor in disclosing and 
explaining genetic test results to patients. The finding of a letter in the mail being least 
preferred as a method of communication of all VUS results being downgraded may be 
due to the indirect nature of the communication method. A letter in the mail forces the 
patient to call with any questions. This is consistent with results of the 2019 study by 
Williamson et al., which assessed how different communication techniques used for 
cancer results influences a patient’s understanding and anxiety. Similarly, our study 
showed that communication through direct methods (i.e., telephone or in person) were 
preferred and could lead to better understanding of the results compared to the less direct 
methods of communication (i.e., letter in the mail).  
2.5.3 Level of Concern Regarding VUS Result 
According to Litchfield et al. (2014), communication of test results is complex 
and healthcare workers should take patient’s anxiety levels into consideration for the 
communication method chosen to explain test results. In this study, we examined 
patient’s reported level of concern and how often they think about their VUS result. 
Patients expressed differing levels of concern regarding their uncertain results. Most of 
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the participants expressed mild concern regarding their VUS result and would “rarely 
think about it.” One participant expressed that they are “mildly concerned when [they 
are] reminded of the variant.”  When explaining a reclassified variant, it would be 
important to remind the patient of their initial testing and result because significant time 
may have passed, and patients may not recall all the information regarding their initial 
result. This is supported in this study by most patients reporting rarely thinking about 
their result and having only mild concern regarding their result. A participant who 
reported being concerned expressed that “the unknown is troubling,” so describing the 
details of a reclassified VUS result could help ease some of the concern regarding the 
unknown. A VUS result that is reclassified to “likely pathogenic” or “pathogenic” 
impacts the patient and their family, so it is important to consider how patients feel about 
the VUS for themselves and their family and the impact the reclassification may have. 
Participants conveyed concern with regards to the “possibility of [their] children 
inheriting the VUS…” which demonstrates that they understand the inheritance pattern 
and that a VUS could impact their family members. Since most participants shared that 
they were mildly concerned regarding their VUS result and that they rarely think about it, 
a genetic counselor’s preference for communication method may not be impacted by a 
patient’s level of anxiety regarding an uncertain result. However, it could be important to 
consider how an upgraded result could cause anxiety and select a more direct 





2.5.4 Patient Communication of VUS Result 
 When someone is found to have a VUS result, it is not typically recommended 
that other family members undergo genetic testing for the specific variant (Gradishar et 
al., 2020). In this study, most participants reported that they discussed their VUS result 
with family members. All participants who responded stated that they would share an 
upgraded VUS result with their family and a majority indicated they would tell their 
family about a downgraded VUS result. These responses suggest that participants 
understand that sharing this information allows family members to have reassurance 
about the uncertain result and confirms that they do not need to undergo genetic testing 
for the specific variant. A potential reason behind all participants stating that they would 
share an upgraded result is due to their understanding that an upgraded result could lead 
to family cascade testing and have implications for their family members’ healthcare 
(Halverson, 2019; Halverson et al., 2020).  
2.6 Limitations and Future Research 
This study had several limitations. The conclusions able to be drawn from this 
research are limited because the responses from participants were voluntary. The 
participant sample was biased, since all of the patients were recruited from Prisma Health 
cancer genetic counseling. Another limitation of this study was the low response rate 
among the patients who were mailed letters resulting in a small sample size. Due to the 
low response rate, no generalized recommendations could be made for a standardized 
guideline for genetic counselors to utilize when informing patients of a reclassified VUS 
result. Additionally, recall bias may have influenced participants’ responses since some 
may have received their VUS result as long as two years ago. Though the majority of 
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participants received their VUS result within the last year, their understanding of the 
result and implications of a reclassification may have changed overtime. While rank 
order items allowed participants to list preferences of communication methods, it is a 
stringent technique. Participants may not have a preference between two communication 
methods but would have had to rank a preference.  
Future studies could explore the perspectives of patients from other healthcare 
systems to get a larger sample and more generalizable data. A number of participants 
would not want to be seen in-person regarding a reclassified VUS result, even when the 
result is upgraded, which could partially be due to barriers to genetic counseling. Future 
studies could assess if the participants’ rank order would change with the addition of 
telemedicine as an option for receiving a VUS result reclassification. Additionally, future 
studies may want to include additional qualitative questions to learn why participants 
ranked communication methods the way that they did. This study looked at a hypothetical 
situation of a VUS result being reclassified, so future studies could compare answers 
between a group of patients who have had a VUS reclassified already versus a 
hypothetical VUS reclassification. As more patients undergo a VUS reclassification, it 
may be beneficial to investigate how different genetic counselors, genetic professionals, 
and other healthcare providers discuss this information with patients.  
Overall, recommending guidelines for healthcare providers regarding 
communication methods for reclassified VUS results was not achievable because there 
was no clear participant preference. However, important factors to consider for genetic 
counselors to consider include patient anxiety, patient preferences, and the specific 
variant reclassification. Cancer genetic counselors could consider discussing 
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communication method preferences with their patients during the appointment to 
establish a personalized way to recontact each patient. 
Table 2.1 Participants demographic information 
Category Responses Total (n) Percent (%) 
Age Group (N=29) 
 
20-30 2 6.90% 
 30-40 3 10.34% 
 40-50 8 27.59% 
 50-60 8 27.59% 
 60-70 7 24.14% 
 70+ 2 3.45% 
Sex (N=33) Female 31 93.94% 
 Male 2 6.06% 
Race/Ethnicity (N=33) 
 











 Spanish/Hispanic/Latino 2 6.06% 
 Asian Indian 0 0.00% 
 Chinese 1 3.03% 
 Japanese 0 0.00% 
 Other Asian 0 0.00% 
 





Highest Level of 
Education (N=32) 
 
No education 0 0.00% 
 Middle school 0 0.00% 
 Some high school 0 0.00% 
 High school graduate 1 3.03% 
 Some college 8 24.24% 
 Associate degree 4 12.12% 
 Bachelor’s degree 12 36.36% 
 Master’s degree 6 18.18% 
 Professional degree 1 3.03% 
 Doctorate degree 1 3.03% 
Informed of VUS result 1-6 months ago 10 30.30% 
 7-12 months ago 11 33.33% 
 12-18 months ago 11 33.33% 
 19-24 months ago 2 6.06% 
 
Table 2.2 Number of participants who ranked each method of communication for 
UPGRADED (1= most preferred; 6= least preferred) 
 
 One Two Three Four Five Six 
Letter in the mail 
 
9 8 7 5 5 0 
Telephone call by a 
genetic counselor 
 
16 14 3 0 1 0 
Telephone call by 
medical assistant 
 
3 8 11 7 4 1 
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In-person 
appointment with a 
genetic counselor 
 
3 2 7 11 8 3 
Secure web-portal 
 
1 1 6 11 12 3 
Other 2 1 0 0 4 27 
 
Table 2.3 Number of participants who ranked each method of communication for 
DOWNGRADED (1= most preferred; 6= least preferred) 
 
 One Two Three Four Five Six 
Letter in the mail 
 
17 5 5 2 3 0 
Telephone call by a 
genetic counselor 
 
10 14 7 0 1 0 
Telephone call by 
medical assistant 
 
1 11 12 8 0 0 
In-person 
appointment with a 
genetic counselor 
 
0 0 4 13 13 2 
Secure web-portal 
 
3 2 4 8 12 3 
Other 1 0 0 1 3 27 
 
Table 2.4 Participant’s level of concern regarding their VUS result  
Level of concern  Number of Participants (n) Percent (%) 
Not concerned 5 14.71% 
Mildly concerned  19 55.88% 
Moderately concerned 4 11.76% 








Figure 2.2 Number of participants who would NOT want a specific communication 

















































































































Figure 2.3 Number of participants who would NOT want a specific communication 
method for notification of VUS being DOWNGRADED 
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Figure 2.7 Personal history of cancer  
 
 








































Cancer genetic counseling services are available for patients with personal and or 
family history that is suspicious of a hereditary cause of cancer. Genetic testing allows 
patients to understand their inherited cancer risk. As more people undergo genetic testing, 
there is a higher diagnostic yield overall along with more uncertain results. However, as 
technology improves and more is learned about cancer predisposition genes, there is a 
higher chance for variant reclassification to occur. Cancer genetic counselors should be 
aware of an increased rate of reclassified VUS results and consider how they desire to 
update patients regarding this information. There is no standard guideline for healthcare 
providers of how to deliver reclassified VUS results. Knowing how patient 
communication preferences differ based on if the VUS was upgraded, if the VUS was 
downgraded, or the number of VUS results are important factors to consider when 
determining a standardized method for result disclosure of a reclassified VUS result. 
Considering the present data, it was not possible to make definitive recommendations for 
healthcare providers regarding delivery of reclassified VUS results. Since the participants 
did not have a strong preference, healthcare providers can consider using a 
communication method that is best for their clinic based on the capabilities including 
time and resources.  Findings from this study can inform genetic counselors that patient 
preferences, patient anxiety, and type of variant reclassification are all factors that can 
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APPENDIX A  
INITIATIAL PARTICIPANT RECRUITMENT LETTER 
Dear Patient,   
I am writing to invite you to participate in a University of South Carolina Master 
in Genetic Counseling student thesis project. Cooper Hall is working towards completing 
her master’s degree and is conducting research to learn how patients would like to be 
notified if their uncertain cancer genetic results are updated by the genetic testing 
laboratory.  
You are receiving this letter because you underwent cancer genetic counseling 
and your test results revealed a variant of uncertain significance (VUS). A VUS means 
that there is a change in one of your genes, but we do not know if this change is harmful 
(also called a positive) or normal (also called negative). The goal of this research project 
is to understand how patients prefer to receive updated information if their variant of 
uncertain significance (VUS) test result is reclassified to either positive or negative. We 
aim to utilize the information learned in this study to help healthcare providers deliver 
better quality care for their patients.  
The survey will ask you to rate how you would prefer to be notified if your VUS 
result is updated and will also include questions about your VUS result and demographic 
information. You may find it beneficial to have a copy of your genetic test results 
available for you to look at while you take this survey. Participation in this study 
involves the completion of an online survey that will be available until December 15th at 
midnight. The survey will be available online through Qualtrics and should take no more 
than 15 minutes to complete. Participation in this study is voluntary. You are giving 
consent for your participation in this study by finishing and submitting the online survey. 
At any time during the survey, you may exit and not complete the survey. All responses 
from the survey will be anonymous and no identifying information will be recorded.  If 
you complete this survey, you may choose to enter a raffle for a chance to win one of five 
$20.00 gift cards for Amazon.  
 If you are interested in taking this survey, please enter the following link into your 






Thank you for your consideration to participate in this study. Your involvement is 
exceedingly valuable as it will help healthcare providers better communicate updated  
genetic test results with patients that have received a VUS result. If you have any 
questions or trouble with the online survey, please reach out to myself or Cooper Hall, 
the primary investigator. 
 
Sincerely,  
Counselor name    Cooper N. Hall, BS 









































PARTICIPANT SECOND RECRUITMENT LETTER 
Survey deadline extension to Dec 15th, 2020 at Midnight. If you have already 
completed the survey, please disregard this letter. 
Dear Patient,  
I am writing to invite you to participate in a University of South Carolina Master 
in Genetic Counseling student thesis project. Cooper Hall is working towards completing 
her master’s degree and is conducting research to learn how patients would like to be 
notified if their uncertain cancer genetic results are updated by the genetic testing 
laboratory.  
You are receiving this letter because you underwent cancer genetic counseling 
and your test results revealed a variant of uncertain significance (VUS). A VUS means 
that there is a change in one of your genes, but we do not know if this change is harmful 
(also called a positive) or normal (also called negative). The goal of this research project 
is to understand how patients prefer to receive updated information if their variant of 
uncertain significance (VUS) test result is reclassified to either positive or negative. We 
aim to utilize the information learned in this study to help healthcare providers deliver 
better quality care for their patients.  
The survey will ask you to rate how you would prefer to be notified if your VUS 
result is updated and will also include questions about your VUS result and demographic 
information. You may find it beneficial to have a copy of your genetic test results 
available for you to look at while you take this survey. Participation in this study 
involves the completion of an online survey that has been extended to December 15th at 
midnight. If you have already taken the survey, please ignore this letter, and do not take 
the survey again. The survey will be available online through Qualtrics and should take 
no more than 15 minutes to complete. Participation in this study is voluntary. You are 
giving consent for your participation in this study by finishing and submitting the online 
survey. At any time during the survey, you may exit and not complete the survey. All 
responses from the survey will be anonymous and no identifying information will be 
recorded.  If you complete this survey, you may choose to enter a raffle for a chance to 
win one of five $20.00 gift cards for Amazon.  
 If you are interested in taking this survey, please enter the following link into your 






Thank you for your consideration to participate in this study. Your involvement is 
exceedingly valuable as it will help healthcare providers better communicate updated 
genetic test results with patients that have received a VUS result. If you have any 
questions or trouble with the online survey, please reach out to myself or Cooper Hall, 
the primary investigator. 
 
Sincerely,  
Counselor name    Cooper N. Hall, BS 




















PARTICIPANT ONLINE QUESTIONNAIRE INTRODUCTION  
Thank you for your interest in participating in my master's research project. Please 
review the study details below prior to completing this survey.  
  
PURPOSE AND BACKGROUND: 
You are being asked to participate in a research study conducted by Cooper Hall, a 
Master of Science in Genetic Counseling Student at University of South Carolina. This 
study aims to assess how patients wish to receive news of an amended variant of 
uncertain significance result. You are being asked to participate in this survey because 
your genetic test results revealed a variant of uncertain significance (VUS) identified on 
cancer genetic testing. A VUS means there is a change in one of your genes, but we do 
not know if this change is a harmful (also called pathogenic/mutation) or normal (also 
called benign/negative).  
  
You may find it beneficial to have a copy of your genetic test results available to 
look at while you take this survey. 
  
DURATION: 
Participation in this survey should take no more than 15 minutes 
  
PARTICIPATION: 
Participation in this study is voluntary. You may choose to exit the survey at any time. 
You may skip individual questions in the survey that you are uncomfortable answering. 
All answers collected in the survey will remain anonymous and confidential. The data 
will be stored in a secure device and can only be viewed by the primary investigator. In 
the event that you withdraw participation in this study, the information provided will be 
kept in a confidential manner and discarded at the conclusion of the study.  
  
PAYMENT: 
We thank you for your interest, time, and participation in this survey.  If you complete 
this survey, there will be a final optional question where you can be entered into a raffle 
for a $20.00 gift card to Amazon. If you select “Yes” at the end of the survey, then it 
will redirect you to a new survey to enter your name and email address for the chance to 





By completing this survey, you are consenting for your data to be used in this study and 
any future research, presentations, or publications related to this project.  
 
If you have any questions, please contact Cooper Hall, by email 
(cooper.hall@uscmed.sc.edu) or phone (714-624-0111).  
  





ONLINE QUALTRICS QUESTIONNAIRE FOR PARTICIPANTS   
1. Question: When were you informed that you have a Variant of Uncertain 
Significance? 
o 1-6 months ago  
o 7-12 months ago 
o 13-18 months ago  
o 19-24 months ago  
2. Question: How would you prefer to be notified if your Variant of Uncertain 
Significance (VUS) was reclassified from VUS to harmful or likely harmful 
(UPGRADED)? Please drag and drop the following options so that 1 is the way 
you would most prefer to be notified and 6 is the way you would least prefer to 
be notified.  (1 most preferred; 6= least preferred) 
o ______ Letter in the mail  
o ______ Telephone call by a genetic counselor  
o ______ Telephone call by medical assistant (or other healthcare provider)  
o ______ In-person appointment with a genetic counselor  
o ______ Secure web-portal  
o ______ Other (Please specify)  
3. Question: Are there any methods that you would NOT like to be used to notify 
you if your VUS was UPGRADED? Select all that apply. 
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
4. Question: How would you prefer to be notified if your Variant of Uncertain 
Significance (VUS) was reclassified from VUS to normal (DOWNGRADED)? 
Please drag and drop the following options so that 1 is your most preferred way 
you would like to be notified ant 6 is your least preferred way you would like to 
be notified.  (1 most preferred; 6= least preferred) 
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o ______ Letter in the mail  
o ______ Telephone call by a genetic counselor  
o ______ Telephone call by medical assistant (or other healthcare provider)  
o ______ In-person appointment with a genetic counselor  
o ______ Secure web-portal  
o ______ Other (Please specify)  
5. Question: Are there any methods that you would NOT like to be used to notify 
you if your VUS was DOWNGRADED? Select all that apply 
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
6. Question: If you have more than one Variant of Uncertain Significance, would 
you prefer to be notified once when all of the VUS have been changed or would 
you prefer to be notified each time a VUS is changed? 
o When all of the VUS have been changed 
o Each time a VUS is changed 
o I only had one VUS  
7. Question: If you had multiple VUS on your genetic test results but only one has 
been reclassified from VUS to normal, which of the following would be your 
most preferred method of notification?  
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
8. Question: If you had multiple VUS on your genetic test results but only one has 
been reclassified from VUS to normal, which of the following would be 
your least preferred method of notification?  
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
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9. Question: If you had multiple VUS on your genetic test results and all were 
reclassified, which of the following would be your most preferred method of 
notification?  
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
10. Question: If you had multiple VUS on your genetic test results and all were 
reclassified, which of the following would be your least preferred method of 
notification?  
o Letter in the mail  
o Telephone call by a genetic counselor  
o Telephone call by medical assistant (or other healthcare provider)  
o In-person appointment with a genetic counselor  
o Secure web-portal  
o Other (Please specify) 
11. Question: Generally speaking, how concerned are you with your Variant of 
Uncertain Significance genetic test result? 
o Not concerned  
o Mildly concerned   
o Moderately concerned  
o Concerned  
o Severely Concerned 
12. Question: How often do you think about your VUS genetic test result? 
o Not at all  
o Rarely think about it   
o Sometimes think about it   
o Think about it frequently   
13. Question: Please explain why you selected your answers above 
14. Question: Do you have a personal history of cancer? 
o Yes 
o No 
15. Question: Please select which indication closely aligns with your history (select 
all that apply) 
o Breast/ovarian cancer 
o Colon cancer/colon polyps  
o Endocrine tumors/cancer (such as thyroid cancer, parathyroid, 
pheochromocytoma) 
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o Colon cancer/ endometrial cancer 
o Other (Please specify)   
16. Question: Do you have a family history of cancer? 
o Yes 
o No 
17. Question: Please select which indication closely aligns with your history (select 
all that apply) 
o Breast/ovarian cancer 
o Colon cancer/colon polyps  
o Endocrine tumors/cancer (such as thyroid cancer, parathyroid, 
pheochromocytoma) 
o Colon cancer/ endometrial cancer 
o Other (Please specify) 
18. Question: If you have a copy of your genetic test report available, please review 
and list the gene(s) that had a VUS (e.g.: BRCA1, BRCA2, ATM, TP53, APC). If 
unsure write "NA" 
19. Question: Have you discussed your VUS result with any of your family 
members?  
o Yes  
o No 
20. Question: Will you tell your family if your VUS result was UPGRADED?  
o Yes 
o No 
21. Question: Will you tell your family if your VUS result was DOWNGRADED?  
o Yes 
o No 
22. Question: Would you have preferred more or less information when you first 
received your VUS result?  
o I would have liked to have had a longer/more detailed discussion 
o I would have liked to have less details  
o The amount of information was just right 
DEMOGRAPHIC INFORMATION 
1. Question: Your current age (in years) 
2. Question: Sex 
o Male  
o Female 
o Other 
o Prefer not to answer 
3. Question:  Race/ Ethnicity  
o White/Caucasian  
o Black/African American/ African   
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o American Indian or Alaska Native   
o Spanish/Hispanic/Latino    
o Asian Indian   
o Chinese   
o Japanese  
o Other Asian  
o Native Hawaiian or Pacific Islander  
o Other ethnicity (Please specify) 
4. Question: Highest Level of Education  
o No education   
o Middle school    
o Some high school   
o High school graduate (e.g., Diploma or GED)  
o Some college  
o Associate degree (e.g., AA, AS)  
o Bachelor’s degree (e.g., BS, BA)  
o Master’s degree (e.g., MA, MS, MBA)  
o Professional degree (e.g., MD, DDS, DVM, LLB, JD)  
o Doctorate degree (e.g., PhD)  















PARTIPANT ONLINE QUESTIONNAIRE THANK YOU PAGE 
Thank you for taking the time to complete our survey. Your participation is greatly 
appreciated.  This study will be valuable for healthcare providers to gain insight into how 
patients wish to receive reclassified test results so that they can offer the best care to 
patients. 
 
You have reached the end of the survey, but you have not officially submitted your 
responses yet.   
 
If you would like to be entered into a raffle drawing for one of five $20.00 Amazon gift 
cards, please copy the link below into a new browser window to enter your name and 
email address. Please do so BEFORE submitting your survey, as the link will not be 
available to you after closing this page.   
 



















PARTICIPANT ONLINE RAFFLE INTRODUCTION 
By entering your information on the following page, you are willingly entering the raffle 
for one of five $20.00 Amazon gift cards.  
 
You are eligible for this raffle because you completed the research questionnaire, "Patient 
Communication Preference Regarding Reclassified Genetic Test Results". Your 
information will not be distributed and will not be used to contact you unless you are the 
winner of the raffle. 
 
If you would like to enter the raffle, please click the bottom button below. If not, please 





















PARTICIPANT ONLINE RAFFLE ENTRY 
Please remember to submit this survey by hitting the blue arrow below   
 
1. Please complete the form below: 
• First Name: 
• Last Name: 
• Preferred Title (Mr., Ms., Dr.): 
• Preferred Email: 
 
